| 1 | Promoting Reasonable Career Expectations and Maximizing Professional Fulfillment for Academic Oncologists: ASCO Recommendations for Academic Medical Centers | 16.9 | 6 | Citations (PDF) |
| 2 | The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention | 4.0 | 29 | Citations (PDF) |
| 3 | Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy | 4.6 | 46 | Citations (PDF) |
| 4 | Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance) | 2.9 | 16 | Citations (PDF) |
| 5 | Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance) | 1.9 | 12 | Citations (PDF) |
| 6 | First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer | 6.8 | 28 | Citations (PDF) |
| 7 | Reply to M. Hutton-Potts and A.M. Joshua | 2.9 | 0 | Citations (PDF) |
| 8 | Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors | 22.5 | 145 | Citations (PDF) |
| 9 | Bridging the Gap Among Clinical Practice Guidelines for Pain Management in Cancer and Sickle Cell Disease | 2.9 | 1 | Citations (PDF) |
| 10 | Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial | 16.9 | 71 | Citations (PDF) |
| 11 | Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up | 3.4 | 8 | Citations (PDF) |
| 12 | Hydroxyapatite mineral enhances malignant potential in a tissue-engineered model of ductal carcinoma in situ (DCIS) | 12.1 | 31 | Citations (PDF) |
| 13 | Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial) | 2.3 | 34 | Citations (PDF) |
| 14 | Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update | 16.9 | 577 | Citations (PDF) |
| 15 | Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer | 16.9 | 267 | Citations (PDF) |
| 16 | Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer | 6.6 | 9 | Citations (PDF) |
| 17 | Obesity-associated Breast Inflammation among Hispanic/Latina Breast Cancer Patients | 1.5 | 15 | Citations (PDF) |
| 18 | The Impact of Obesity on Breast Cancer | 4.2 | 116 | Citations (PDF) |
| 19 | A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease | 1.5 | 24 | Citations (PDF) |
| 20 | Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection | 2.3 | 19 | Citations (PDF) |
| 21 | Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer | 2.3 | 48 | Citations (PDF) |
| 22 | Adiposity, Inflammation, and Breast Cancer Pathogenesis in Asian Women | 1.5 | 40 | Citations (PDF) |
| 23 | Correlative imaging reveals physiochemical heterogeneity of microcalcifications in human breast carcinomas | 2.3 | 53 | Citations (PDF) |
| 24 | The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers | 33.0 | 902 | Citations (PDF) |
| 25 | Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study | 2.3 | 6 | Citations (PDF) |
| 26 | Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer | 6.8 | 88 | Citations (PDF) |
| 27 | Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up | 2.9 | 10 | Citations (PDF) |
| 28 | Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative) | 0.7 | 8 | Citations (PDF) |
| 29 | Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score | 3.0 | 32 | Citations (PDF) |
| 30 | Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index | 1.5 | 128 | Citations (PDF) |
| 31 | The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials | 4.9 | 92 | Citations (PDF) |
| 32 | Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience | 3.4 | 34 | Citations (PDF) |
| 33 | Menopause Is a Determinant of Breast Aromatase Expression and Its Associations With BMI, Inflammation, and Systemic Markers | 4.0 | 97 | Citations (PDF) |
| 34 | Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance) | 3.1 | 8 | Citations (PDF) |
| 35 | Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment | 16.5 | 2,060 | Citations (PDF) |
| 36 | The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis | 2.3 | 36 | Citations (PDF) |
| 37 | MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer | 6.8 | 633 | Citations (PDF) |
| 38 | RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer | 2.3 | 47 | Citations (PDF) |
| 39 | Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance) | 2.3 | 81 | Citations (PDF) |
| 40 | Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer | 3.4 | 35 | Citations (PDF) |
| 41 | Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302) | 2.3 | 15 | Citations (PDF) |
| 42 | Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design | 6.4 | 94 | Citations (PDF) |
| 43 | Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer | 2.3 | 21 | Citations (PDF) |
| 44 | 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer | 2.3 | 35 | Citations (PDF) |
| 45 | Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow‐up | 4.0 | 18 | Citations (PDF) |
| 46 | Effects of Rapid Weight Loss on Systemic and Adipose Tissue Inflammation and Metabolism in Obese Postmenopausal Women | 0.3 | 70 | Citations (PDF) |
| 47 | American Society of Clinical Oncology Summit on Addressing Obesity Through Multidisciplinary Provider Collaboration: Key Findings and Recommendations for Action | 4.0 | 13 | Citations (PDF) |
| 48 | A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer | 4.7 | 54 | Citations (PDF) |
| 49 | Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research Statement | 16.9 | 102 | Citations (PDF) |
| 50 | Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact | 2.3 | 21 | Citations (PDF) |
| 51 | Docosahexaenoic Acid Supplementation is Not Anti- Inflammatory in Adipose Tissue of Healthy Obese Postmenopausal Women | 0.2 | 9 | Citations (PDF) |
| 52 | Twenty‐one–gene recurrence score assay in BRCA‐associated versus sporadic breast cancers: Differences based on germline mutation status | 4.0 | 55 | Citations (PDF) |
| 53 | Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology | 12.6 | 287 | Citations (PDF) |
| 54 | PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance) | 6.4 | 104 | Citations (PDF) |
| 55 | Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation | 16.9 | 916 | Citations (PDF) |
| 56 | Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer | 3.4 | 55 | Citations (PDF) |
| 57 | 26 Vlcd-Induced Rapid Weight Loss Is Accompanied by Enhanced Lipolysis, Altered Adipose Tissues With Concomitant Changes in the Fecal Microbiome and Plasma Metabolome | 0.9 | 1 | Citations (PDF) |
| 58 | Exocytosis of macrophage lysosomes leads to digestion of apoptotic adipocytes and foam cell formation | 3.6 | 117 | Citations (PDF) |
| 59 | The epichaperome is an integrated chaperome network that facilitates tumour survival | 37.9 | 297 | Citations (PDF) |
| 60 | White adipose tissue inflammation and cancer‐specific survival in patients with squamous cell carcinoma of the oral tongue | 4.0 | 48 | Citations (PDF) |
| 61 | A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling | 6.8 | 216 | Citations (PDF) |
| 62 | Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy | 4.2 | 166 | Citations (PDF) |
| 63 | Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer | 2.3 | 14 | Citations (PDF) |
| 64 | Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update | 2.7 | 167 | Citations (PDF) |
| 65 | Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update | 16.9 | 238 | Citations (PDF) |
| 66 | Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance) | 2.3 | 83 | Citations (PDF) |
| 67 | Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic review | 6.4 | 13 | Citations (PDF) |
| 68 | Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years | 34.5 | 596 | Citations (PDF) |
| 69 | Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received | 16.9 | 622 | Citations (PDF) |
| 70 | Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis | 4.6 | 100 | Citations (PDF) |
| 71 | Response | 4.6 | 1 | Citations (PDF) |
| 72 | Noninvasive Detection of Inflammatory Changes in White Adipose Tissue by Label-Free Raman Spectroscopy | 6.5 | 25 | Citations (PDF) |
| 73 | Obesity and Cancer—Opportunities to Break the Link | 0.8 | 7 | Citations (PDF) |
| 74 | A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer | 2.3 | 2 | Citations (PDF) |
| 75 | Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression | 16.9 | 288 | Citations (PDF) |
| 76 | The Genomic Landscape of Male Breast Cancers | 6.8 | 140 | Citations (PDF) |
| 77 | Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer | 6.8 | 184 | Citations (PDF) |
| 78 | Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer | 14.3 | 84 | Citations (PDF) |
| 79 | Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors | 2.3 | 12 | Citations (PDF) |
| 80 | Targeting obesity-related adipose tissue dysfunction to prevent cancer development and progression | 1.9 | 29 | Citations (PDF) |
| 81 | Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer | 14.3 | 156 | Citations (PDF) |
| 82 | Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant | 16.9 | 7 | Citations (PDF) |
| 83 | Estimating the OncotypeDX score: validation of an inexpensive estimation tool | 2.3 | 25 | Citations (PDF) |
| 84 | Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update | 2.3 | 103 | Citations (PDF) |
| 85 | Obesity and Cancer: Concepts and Challenges | 0.5 | 16 | Citations (PDF) |
| 86 | Breast Cancer, Version 1.2016 | 12.6 | 147 | Citations (PDF) |
| 87 | Breast Cancer Version 2.2015 | 12.6 | 169 | Citations (PDF) |
| 88 | What Is the Optimum Timing of Postmastectomy Radiotherapy in Two-Stage Prosthetic Reconstruction | 1.9 | 213 | Citations (PDF) |
| 89 | Impact of Neoadjuvant Chemotherapy in Stage II–III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates | 4.6 | 189 | Citations (PDF) |
| 90 | Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer | 34.5 | 707 | Citations (PDF) |
| 91 | Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer | 2.3 | 87 | Citations (PDF) |
| 92 | Obesity and Cancer: Local and Systemic Mechanisms | 18.7 | 260 | Citations (PDF) |
| 93 | Science and Society: Fifty Years Later—The 2014 Presidential Address | 16.9 | 2 | Citations (PDF) |
| 94 | The Development of Dose-Dense Adjuvant Chemotherapy | 4.0 | 13 | Citations (PDF) |
| 95 | American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options | 16.9 | 883 | Citations (PDF) |
| 96 | International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013) | 1.7 | 49 | Citations (PDF) |
| 97 | Bilateral Mastectomy versus Breast-Conserving Surgery for Early-Stage Breast Cancer | 1.9 | 131 | Citations (PDF) |
| 98 | Estrogen Protects against Obesity-Induced Mammary Gland Inflammation in Mice | 1.5 | 35 | Citations (PDF) |
| 99 | Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype | 5.5 | 100 | Citations (PDF) |
| 100 | Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial) | 2.3 | 78 | Citations (PDF) |
| 101 | Menopause Is a Determinant of Breast Adipose Inflammation | 1.5 | 106 | Citations (PDF) |
| 102 | Combination Trastuzumab and Chemotherapy May Have a Role in Women With Small, Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer | 16.9 | 2 | Citations (PDF) |
| 103 | Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction | 3.4 | 29 | Citations (PDF) |
| 104 | Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance) | 4.6 | 60 | Citations (PDF) |
| 105 | Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma | 5.1 | 141 | Citations (PDF) |
| 106 | Obesity-dependent changes in interstitial ECM mechanics promote breast tumorigenesis | 12.5 | 315 | Citations (PDF) |
| 107 | Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology Statement | 16.9 | 53 | Citations (PDF) |
| 108 | Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020) | 2.3 | 92 | Citations (PDF) |
| 109 | Web based pathology assessment in RTOG 98-04 | 1.7 | 6 | Citations (PDF) |
| 110 | American Society of Clinical Oncology Position Statement on Obesity and Cancer | 16.9 | 485 | Citations (PDF) |
| 111 | Building a Rapid Learning Health Care System for Oncology: The Regulatory Framework of CancerLinQ | 16.9 | 101 | Citations (PDF) |
| 112 | Comorbidity, Chemotherapy Toxicity, and Outcomes Among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer on a Clinical Trial: CALGB 49907 and CALGB 361004 (Alliance) | 2.9 | 75 | Citations (PDF) |
| 113 | Diminishing Relative Contraindications for Immediate Breast Reconstruction | 1.9 | 45 | Citations (PDF) |
| 114 | A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer | 2.3 | 96 | Citations (PDF) |
| 115 | Maastricht Delphi Consensus on Event Definitions for Classification of Recurrence in Breast Cancer Research | 4.6 | 98 | Citations (PDF) |
| 116 | Impact of obesity on the survival of patients with early‐stage squamous cell carcinoma of the oral tongue | 4.0 | 71 | Citations (PDF) |
| 117 | Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update | 16.9 | 724 | Citations (PDF) |
| 118 | Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901 | 2.1 | 37 | Citations (PDF) |
| 119 | Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance) | 16.9 | 74 | Citations (PDF) |
| 120 | Breast Cancer Version 3.2014 | 12.6 | 171 | Citations (PDF) |
| 121 | Omega-3 Fatty Acids for Prevention of Breast Cancer: an Update and the State of the Science | 0.8 | 23 | Citations (PDF) |
| 122 | Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis | 2.2 | 26 | Citations (PDF) |
| 123 | ESR1 ligand-binding domain mutations in hormone-resistant breast cancer | 25.2 | 1,161 | Citations (PDF) |
| 124 | Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer | 6.8 | 681 | Citations (PDF) |
| 125 | Dietary Polyphenols Suppress Elevated Levels of Proinflammatory Mediators and Aromatase in the Mammary Gland of Obese Mice | 1.5 | 38 | Citations (PDF) |
| 126 | A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer | 2.3 | 67 | Citations (PDF) |
| 127 | A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors | 4.7 | 98 | Citations (PDF) |
| 128 | A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901 | 1.8 | 14 | Citations (PDF) |
| 129 | Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer | 2.3 | 30 | Citations (PDF) |
| 130 | Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer | 4.0 | 189 | Citations (PDF) |
| 131 | PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer | 2.3 | 103 | Citations (PDF) |
| 132 | Molecular Pathways: Adipose Inflammation as a Mediator of Obesity-Associated Cancer | 6.8 | 327 | Citations (PDF) |
| 133 | Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy | 6.8 | 57 | Citations (PDF) |
| 134 | Epoetin Alfa: To Give or Not to Give | 4.6 | 1 | Citations (PDF) |
| 135 | Pilot study of 68Ga-DOTA-F(ab′)2-trastuzumab in patients with breast cancer | 1.1 | 80 | Citations (PDF) |
| 136 | Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab | 6.8 | 67 | Citations (PDF) |
| 137 | ASCO's Approach to a Learning Health Care System in Oncology | 2.9 | 49 | Citations (PDF) |
| 138 | Caloric Restriction Reverses Obesity-Induced Mammary Gland Inflammation in Mice | 1.5 | 49 | Citations (PDF) |
| 139 | Electrophysiological Features of Taxane-Induced Polyneuropathy in Patients With Breast Cancer | 1.4 | 32 | Citations (PDF) |
| 140 | Acupuncture in the treatment of upper‐limb lymphedema | 4.0 | 66 | Citations (PDF) |
| 141 | Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer | 2.6 | 58 | Citations (PDF) |
| 142 | Risk of metachronous breast cancer after BRCA mutation–associated ovarian cancer | 4.0 | 67 | Citations (PDF) |
| 143 | Long‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer | 4.0 | 19 | Citations (PDF) |
| 144 | Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer | 1.5 | 67 | Citations (PDF) |
| 145 | Time to Adjuvant Chemotherapy for Breast Cancer in National Comprehensive Cancer Network Institutions | 4.6 | 110 | Citations (PDF) |
| 146 | Breast Cancer, Version 3.2013 | 12.6 | 149 | Citations (PDF) |
| 147 | Obesity and Inflammation: New Insights into Breast Cancer Development and Progression | 4.4 | 104 | Citations (PDF) |
| 148 | Obesity and Inflammation: New Insights into Breast Cancer Development and Progression | 4.4 | 111 | Citations (PDF) |
| 149 | Effect of Creatinine Clearance on Patterns of Toxicity in Older Patients Receiving Adjuvant Chemotherapy for Breast Cancer | 3.2 | 22 | Citations (PDF) |
| 150 | Change in Cycle 1 to Cycle 2 Haematological Counts Predicts Toxicity in Older Patients with Breast Cancer Receiving Adjuvant Chemotherapy | 3.2 | 13 | Citations (PDF) |
| 151 | Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor–Negative Breast Cancer | 1.5 | 99 | Citations (PDF) |
| 152 | A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101 | 6.8 | 200 | Citations (PDF) |
| 153 | Can We Really Use Retrospective Subset Analyses and Surveillance, Epidemiology, and End Results Data to Drive Clinical Practice? | 16.9 | 5 | Citations (PDF) |
| 154 | Pioglitazone, a PPARγ Agonist, Suppresses
CYP19
Transcription: Evidence for Involvement of 15-Hydroxyprostaglandin Dehydrogenase and BRCA1 | 1.5 | 25 | Citations (PDF) |
| 155 | The role of targeted therapy and biomarkers in breast cancer treatment | 2.6 | 42 | Citations (PDF) |
| 156 | Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer | 4.0 | 58 | Citations (PDF) |
| 157 | A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints | 27.4 | 69 | Citations (PDF) |
| 158 | Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer | 6.8 | 209 | Citations (PDF) |
| 159 | Adoption of Gene Expression Profile Testing and Association With Use of Chemotherapy Among Women With Breast Cancer | 16.9 | 122 | Citations (PDF) |
| 160 | Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer | 4.0 | 37 | Citations (PDF) |
| 161 | Serum N-Telopeptide and Bone-Specific Alkaline Phosphatase Levels in Patients With Osteonecrosis of the Jaw Receiving Bisphosphonates for Bone Metastases | 1.7 | 18 | Citations (PDF) |
| 162 | Increased Levels of COX-2 and Prostaglandin E2 Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women | 25.1 | 234 | Citations (PDF) |
| 163 | A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors | 6.8 | 62 | Citations (PDF) |
| 164 | Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast‐conservation therapy for lymph node‐negative, human epidermal growth factor receptor 2‐positive breast cancer | 4.0 | 86 | Citations (PDF) |
| 165 | Radiation field design and regional control in sentinel lymph node‐positive breast cancer patients with omission of axillary dissection | 4.0 | 26 | Citations (PDF) |
| 166 | Long‐term outcomes in breast cancer patients undergoing immediate 2‐stage expander/implant reconstruction and postmastectomy radiation | 4.0 | 124 | Citations (PDF) |
| 167 | Current or recent pregnancy is associated with adverse pathologic features but not impaired survival in early breast cancer | 4.0 | 101 | Citations (PDF) |
| 168 | Favorable prognosis in patients with T1a/T1bN0 triple‐negative breast cancers treated with multimodality therapy | 4.0 | 74 | Citations (PDF) |
| 169 | Return to work in low‐income Latina and non‐Latina white breast cancer survivors: A 3‐year longitudinal study | 4.0 | 98 | Citations (PDF) |
| 170 | Metastatic Breast Cancer, Version 1.2012 | 12.6 | 101 | Citations (PDF) |
| 171 | Inflammation and Increased Aromatase Expression Occur in the Breast Tissue of Obese Women with Breast Cancer | 1.5 | 423 | Citations (PDF) |
| 172 | Bone Scans, Bisphosphonates, and a Lack of Acute Changes Within the Mandible | 1.7 | 8 | Citations (PDF) |
| 173 | Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer | 2.3 | 141 | Citations (PDF) |
| 174 | Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer | 4.0 | 17 | Citations (PDF) |
| 175 | Adjuvant trastuzumab with chemotherapy is effective in women with small, node‐negative, HER2‐positive breast cancer | 4.0 | 80 | Citations (PDF) |
| 176 | Obesity Is Associated with Inflammation and Elevated Aromatase Expression in the Mouse Mammary Gland | 1.5 | 346 | Citations (PDF) |
| 177 | p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905) | 6.8 | 31 | Citations (PDF) |
| 178 | A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicin–Cyclophosphamide (AC) Followed by Nanoparticle Albumin–Bound Paclitaxel in Early-Stage Breast Cancer | 6.8 | 29 | Citations (PDF) |
| 179 | MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer | 4.6 | 202 | Citations (PDF) |
| 180 | Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib | 6.8 | 140 | Citations (PDF) |
| 181 | HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab | 6.8 | 426 | Citations (PDF) |
| 182 | Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2
+
breast cancer patients | 7.5 | 335 | Citations (PDF) |
| 183 | Triple-Negative Breast Cancer: An Unmet Medical Need | 3.4 | 697 | Citations (PDF) |
| 184 | The Prostaglandin Transporter Regulates Adipogenesis and
Aromatase
Transcription | 1.5 | 14 | Citations (PDF) |
| 185 | American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women With Early-Stage Invasive Breast Cancer | 16.9 | 60 | Citations (PDF) |
| 186 | Bevacizumab in metastatic breast cancer: when may it be used? | 3.6 | 15 | Citations (PDF) |
| 187 | Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) | 2.3 | 321 | Citations (PDF) |
| 188 | A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer | 2.3 | 49 | Citations (PDF) |
| 189 | Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer | 2.3 | 24 | Citations (PDF) |
| 190 | Abstract C23: Phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer (RESILIENCE). 2011, , | | 0 | Citations (PDF) |
| 191 | Letters: Andrew Seidman, Clifford Hudis, and Eric Winer on the Point-Counterpoint on Dosing for Paclitaxel for Ovarian Cancer (11/25/09 issue); Letters: Simone's OncOpinion: 'Professional Professional Careers for ‘Old’ Guys (12/10/09 issue), by Leonard Zwelling MD; Letters: “Advances in Bone Biology Research Setting Stage for New Cancer Therapies” (11/25/09 issue), by W. Reid Pitts, Jr., MD | 0.1 | 0 | Citations (PDF) |
| 192 | From the Guest Editor: Triple-Negative Breast Cancer | 1.8 | 1 | Citations (PDF) |
| 193 | Breast Cancer: Noninvasive and Special Situations | 12.6 | 11 | Citations (PDF) |
| 194 | Dose Dense Cyclophosphamide, Methotrexate, Fluorouracil is Feasible at 14-Day Intervals: A Pilot Study of Every-14-Day Dosing as Adjuvant Therapy for Breast Cancer | 2.3 | 7 | Citations (PDF) |
| 195 | Pathologic complete response in breast cancer patients receiving anthracycline‐ and taxane‐based neoadjuvant chemotherapy | 4.0 | 49 | Citations (PDF) |
| 196 | Optimizing Chemotherapy Dose and Schedule by Norton-Simon Mathematical Modeling | 0.8 | 37 | Citations (PDF) |
| 197 | Cystoid Macular Edema Secondary tonab-Paclitaxel Therapy | 16.9 | 39 | Citations (PDF) |
| 198 | Estrogen and HER-2 Receptor Discordance Between Primary Breast Cancer and Metastasis | 3.4 | 171 | Citations (PDF) |
| 199 | American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer | 16.9 | 676 | Citations (PDF) |
| 200 | Intravenous Bisphosphonate Therapy Does Not Acutely Alter Nuclear Bone Scan Results | 2.3 | 9 | Citations (PDF) |
| 201 | Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer | 2.3 | 90 | Citations (PDF) |
| 202 | Postmastectomy intensity modulated radiation therapy following immediate expander-implant reconstruction | 2.0 | 54 | Citations (PDF) |
| 203 | Dose-Dense Chemotherapy for Breast Cancer: What Does the Future Hold? | 2.3 | 8 | Citations (PDF) |
| 204 | Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial | 27.4 | 1,343 | Citations (PDF) |
| 205 | The 6q22.33 Locus and Breast Cancer Susceptibility | 1.1 | 22 | Citations (PDF) |
| 206 | cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation | 1.8 | 9 | Citations (PDF) |
| 207 | Phase I Study of Nonpegylated Liposomal Doxorubicin plus Trastuzumab in Patients with HER2-Positive Breast Cancer | 2.3 | 21 | Citations (PDF) |
| 208 | Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals | 33.0 | 644 | Citations (PDF) |
| 209 | The role of adjuvant anthracyclines for breast cancer treatment: Can we use molecular predictors? | 0.8 | 0 | Citations (PDF) |
| 210 | Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer | 34.5 | 534 | Citations (PDF) |
| 211 | Malignant lesion segmentation in contrast‐enhanced breast MR images based on the marker‐controlled watershed | 3.1 | 49 | Citations (PDF) |
| 212 | Mastectomy With Immediate Expander-Implant Reconstruction, Adjuvant Chemotherapy, and Radiation for Stage II–III Breast Cancer: Treatment Intervals and Clinical Outcomes | 1.5 | 56 | Citations (PDF) |
| 213 | Insight into Barriers Against Optimal Adherence to Oral Hormonal Therapy in Women with Breast Cancer | 2.3 | 76 | Citations (PDF) |
| 214 | Prolonged Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel in Breast Cancer Is Feasible | 2.3 | 13 | Citations (PDF) |
| 215 | Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel | 9.5 | 14 | Citations (PDF) |
| 216 | Cyclooxygenase-2-derived Prostaglandin E2 Stimulates Id-1 Transcription | 2.2 | 27 | Citations (PDF) |
| 217 | Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study | 16.9 | 567 | Citations (PDF) |
| 218 | EP2 and EP4 Receptors Regulate Aromatase Expression in Human Adipocytes and Breast Cancer Cells | 2.2 | 86 | Citations (PDF) |
| 219 | Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840 | 16.9 | 570 | Citations (PDF) |
| 220 | Dose-Dense Chemotherapy With Trastuzumab Is an Appropriate Option | 16.9 | 2 | Citations (PDF) |
| 221 | Racial Differences in Clinical Outcomes From Metastatic Breast Cancer: A Pooled Analysis of CALGB 9342 and 9840—Cancer and Leukemia Group B | 16.9 | 33 | Citations (PDF) |
| 222 | Phase I Study of a Novel Capecitabine Schedule Based on the Norton-Simon Mathematical Model in Patients With Metastatic Breast Cancer | 16.9 | 63 | Citations (PDF) |
| 223 | The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in HER-2/neu Overexpressed/Amplified Breast Cancer | 16.9 | 57 | Citations (PDF) |
| 224 | Occult Axillary Node Metastases in Breast Cancer Are Prognostically Significant: Results in 368 Node-Negative Patients With 20-Year Follow-Up | 16.9 | 143 | Citations (PDF) |
| 225 | Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial | 16.9 | 516 | Citations (PDF) |
| 226 | The Taxane Limbo: How Low Can We Go? | 4.6 | 4 | Citations (PDF) |
| 227 | A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma | 2.3 | 13 | Citations (PDF) |
| 228 | Randomized, Controlled Trial of Acupuncture for the Treatment of Hot Flashes in Breast Cancer Patients | 16.9 | 184 | Citations (PDF) |
| 229 | Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience | 16.9 | 316 | Citations (PDF) |
| 230 | HER2 and Response to Paclitaxel in Node-Positive Breast Cancer | 34.5 | 539 | Citations (PDF) |
| 231 | Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2–Overexpressing Breast Cancer: A Phase I Dose-Escalation Study | 16.9 | 338 | Citations (PDF) |
| 232 | Intensive Dose-Dense Compared With High-Dose Adjuvant Chemotherapy for High-Risk Operable Breast Cancer: Southwest Oncology Group/Intergroup Study 9623 | 16.9 | 46 | Citations (PDF) |
| 233 | Breast Cancer Chemotherapy | 1.8 | 15 | Citations (PDF) |
| 234 | Updates in adjuvant systemic treatment of breast cancer | 0.7 | 0 | Citations (PDF) |
| 235 | Endocrine and targeted treatments for breast cancer | 4.7 | 2 | Citations (PDF) |
| 236 | Adjuvant Chemotherapy for Early-Stage Breast Cancer | 2.2 | 3 | Citations (PDF) |
| 237 | Trastuzumab — Mechanism of Action and Use in Clinical Practice | 34.5 | 2,340 | Citations (PDF) |
| 238 | Adjuvant treatment recommendations in older women with breast cancer—A survey of oncologists | 5.0 | 35 | Citations (PDF) |
| 239 | Current status of the taxanes as adjuvant therapy for breast cancer | 2.3 | 1 | Citations (PDF) |
| 240 | A Case Series of Androgen Use in Breast Cancer Survivors with Sexual Dysfunction | 0.5 | 17 | Citations (PDF) |
| 241 | CALGB 9344/CALGB C9741: What have we learned? | 0.5 | 1 | Citations (PDF) |
| 242 | Inadvertent Use of Aromatase Inhibitors in Patients with Breast Cancer with Residual Ovarian Function: Cases and Lessons | 2.3 | 27 | Citations (PDF) |
| 243 | A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer | 2.3 | 91 | Citations (PDF) |
| 244 | Cognitive Function of Older Patients Receiving Adjuvant Chemotherapy for Breast Cancer: A Pilot Prospective Longitudinal Study | 2.9 | 256 | Citations (PDF) |
| 245 | A Prospective, Longitudinal Study of the Functional Status and Quality of Life of Older Patients with Breast Cancer Receiving Adjuvant Chemotherapy | 2.9 | 90 | Citations (PDF) |
| 246 | Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient’s perspective | 2.3 | 89 | Citations (PDF) |
| 247 | Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806 | 2.3 | 26 | Citations (PDF) |
| 248 | Adjuvant Taxanes in the Treatment of Breast Cancer: No Longer at the Tip of the Iceberg | 2.3 | 22 | Citations (PDF) |
| 249 | Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer | 16.5 | 667 | Citations (PDF) |
| 250 | Dietary Fat Reduction and Breast Cancer Outcome: Interim Efficacy Results From the Women's Intervention Nutrition Study | 4.6 | 787 | Citations (PDF) |
| 251 | Radiation Pneumonitis in Breast Cancer Patients Treated with Taxanes: Does Sequential Radiation Therapy Lower the Risk? | 4.0 | 11 | Citations (PDF) |
| 252 | The best use of adjuvant chemotherapy: New drugs and new use of “old” drugs | 2.3 | 5 | Citations (PDF) |
| 253 | Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations inBRCA1 orBRCA2 | 4.0 | 133 | Citations (PDF) |
| 254 | The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999 | 4.0 | 122 | Citations (PDF) |
| 255 | Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane | 4.0 | 173 | Citations (PDF) |
| 256 | Developing a cancer-specific geriatric assessment | 4.0 | 590 | Citations (PDF) |
| 257 | Adjuvant chemotherapy for primary breast cancer | 4.2 | 2 | Citations (PDF) |
| 258 | Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium ?Breast Cancer ? the Development and Validation of New Therapeutics? | 2.3 | 5 | Citations (PDF) |
| 259 | Adjuvant Chemotherapy in Older and Younger Women With Lymph Node–Positive Breast Cancer | 16.5 | 389 | Citations (PDF) |
| 260 | Phosphorylated/Activated HER2 as a Marker of Clinical Resistance to Single Agent Taxane Chemotherapy for Metastatic Breast Cancer | 1.6 | 37 | Citations (PDF) |
| 261 | Weekly Epoetin Alfa During Adjuvant Chemotherapy for Breast Cancer: Effect on Hemoglobin Levels and Quality of Life | 2.3 | 27 | Citations (PDF) |
| 262 | Adjuvant Therapy For Breast Cancer: Practical Lessons From The Early Breast Cancer Trialists' Collaborative Group | 0.8 | 3 | Citations (PDF) |
| 263 | Epoetin Alfa: Future Directions and Future Research | 3.4 | 1 | Citations (PDF) |
| 264 | Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer | 34.5 | 1,036 | Citations (PDF) |
| 265 | Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342 | 16.9 | 262 | Citations (PDF) |
| 266 | HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence In Situ Hybridization | 0.7 | 151 | Citations (PDF) |
| 267 | rHuEPO and Treatment Outcomes: the Clinical Experience | 3.4 | 21 | Citations (PDF) |
| 268 | Dose-dense chemotherapy in breast cancer and lymphoma | 1.9 | 31 | Citations (PDF) |
| 269 | Effect of Cardiac Dysfunction on Treatment Outcomes in Women Receiving Trastuzumab for HER2-Overexpressing Metastatic Breast Cancer | 2.3 | 31 | Citations (PDF) |
| 270 | Cardiac profiles of liposomal anthracyclines | 4.0 | 128 | Citations (PDF) |
| 271 | Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events | 4.0 | 55 | Citations (PDF) |
| 272 | A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy | 4.0 | 42 | Citations (PDF) |
| 273 | Expedition Inspiration Fund for Breast Cancer Research Meeting 2003 | 2.3 | 0 | Citations (PDF) |
| 274 | Epithelial lesions in prophylactic mastectomy specimens from women withBRCA mutations | 4.0 | 94 | Citations (PDF) |
| 275 | Factors influencing treatment patterns of breast cancer patients age 75 and older | 5.0 | 122 | Citations (PDF) |
| 276 | Follow-up care of breast cancer survivors | 5.0 | 16 | Citations (PDF) |
| 277 | The use of taxanes in early breast cancer | 0.5 | 5 | Citations (PDF) |
| 278 | A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment | 4.7 | 269 | Citations (PDF) |
| 279 | Phase II, Randomized, Double-Blind Study of Two Dose Levels of Arzoxifene in Patients With Locally Advanced or Metastatic Breast Cancer | 16.9 | 67 | Citations (PDF) |
| 280 | Prospective Exploratory Analysis of the Association Between Tumor Response, Quality of Life, and Expenditures Among Patients Receiving Paclitaxel Monotherapy for Refractory Metastatic Breast Cancer | 16.9 | 29 | Citations (PDF) |
| 281 | Aromatase Inhibitors in Breast Cancer: An Update | 2.2 | 31 | Citations (PDF) |
| 282 | Adjuvant Use of Taxanes for Patients with Breast Cancer: We See the Tip of the Iceberg | 2.3 | 6 | Citations (PDF) |
| 283 | Risk-Reducing Salpingo-oophorectomy in Women with a BRCA1 or BRCA2 Mutation | 34.5 | 1,428 | Citations (PDF) |
| 284 | Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification | 16.9 | 543 | Citations (PDF) |
| 285 | Response to Letter Regarding High-Dose Chemotherapy for Breast Cancer | 0.1 | 0 | Citations (PDF) |
| 286 | A pilot study of Interpersonal Psychotherapy by telephone with cancer patients and their partners 2000, 9, 44-56 | | 106 | Citations (PDF) |
| 287 | An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel | 2.1 | 6 | Citations (PDF) |
| 288 | Role of Taxanes in Adjuvant Therapy | 1.6 | 6 | Citations (PDF) |
| 289 | Breast Conservation Therapy for Invasive Breast Cancer in Ashkenazi Women With BRCA Gene Founder Mutations | 4.6 | 168 | Citations (PDF) |
| 290 | ADJUVANT THERAPY FOR RESECTABLE BREAST CANCER | 2.2 | 6 | Citations (PDF) |
| 291 | Lack of Increased Cardiac Toxicity with Sequential Doxorubicin and Paclitaxel | 1.6 | 9 | Citations (PDF) |
| 292 | Paclitaxel-Induced Pancreatitis: A Case Report | 4.6 | 17 | Citations (PDF) |
| 293 | Systemic Treatment for Stage I and Stage II Breast Cancer | 1.5 | 0 | Citations (PDF) |
| 294 | Adjuvant Drug Treatment for Resectable Breast Cancer | 3.4 | 3 | Citations (PDF) |
| 295 | New Approaches to Adjuvant Chemotherapy for Breast Cancer | 2.8 | 3 | Citations (PDF) |
| 296 | Is There an Alternative to Alternating Adjuvant Therapy for Breast Cancer? | 1.6 | 2 | Citations (PDF) |
| 297 | Do We Need a “Stopping Rule” for Breast Cancer? | 1.6 | 0 | Citations (PDF) |
| 298 | Phase II trial of carboplatin and etoposide in metastatic breast cancer | 4.0 | 16 | Citations (PDF) |
| 299 | Taxol and Recombinant Human Granulocyte Colony-Stimulating Factor, an Active Regimen as Initial Therapy for Metastatic Breast Cancer. | 4.0 | 2 | Citations (PDF) |
| 300 | A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma | 4.0 | 80 | Citations (PDF) |
